目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 MarketsandMarkets repository analysis
2.2.1.3 Secondary analysis
2.2.1.4 Bottom-up approach (disease indication-based analysis)
2.2.1.5 Primary research
2.2.1.5.1 Insights from primary sources
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN VACCINES MARKET
3.3 DISRUPTIVE TRENDS SHAPING VACCINES MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS
4.1 GLOBAL VACCINES MARKET SNAPSHOT
4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2024
4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 UNMET NEEDS & WHITE SPACES
4.5 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.8 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Focus on vaccine development and launches
5.2.1.2 Rising prevalence of infectious diseases
5.2.1.3 Increasing immunization programs
5.2.1.4 Advancements in vaccine technology
5.2.1.5 Government support and funding for vaccine development
5.2.2 RESTRAINTS
5.2.2.1 High cost of vaccine development
5.2.3 OPPORTUNITIES
5.2.3.1 Rising focus on therapeutic vaccines
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory processes
5.2.4.2 Product recalls

6 INDUSTRY TRENDS
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
6.2 PRICING ANALYSIS
6.2.1 AVERAGE SELLING PRICE TREND OF VACCINES, BY KEY PLAYER, 2023-2025
6.2.2 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2023-2025
6.2.3 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021-2023
6.3 TECHNOLOGY ANALYSIS
6.3.1 KEY TECHNOLOGIES
6.3.1.1 Recombinant technology
6.3.1.2 Conjugation technology
6.3.1.3 Viral vector technology
6.3.2 COMPLEMENTARY TECHNOLOGIES
6.3.2.1 Encapsulation & delivery technology
6.3.2.2 Automation & control
6.3.2.3 AI & machine learning for vaccine design
6.3.3 ADJACENT TECHNOLOGIES
6.3.3.1 Single-use technology
6.3.3.2 Cell line development
6.4 VALUE CHAIN ANALYSIS
6.5 PIPELINE ANALYSIS
6.5.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
6.5.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
6.5.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
6.6 ECOSYSTEM ANALYSIS
6.6.1 VACCINES MARKET: ROLE IN ECOSYSTEM
6.7 REGULATORY ANALYSIS
6.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.7.2 REGULATORY FRAMEWORK
6.7.2.1 North America
6.7.2.2 Europe
6.7.2.3 Asia Pacific
6.7.2.4 Latin America
6.7.2.5 Middle East & Africa
6.7.3 REGULATORY CHALLENGES IN VACCINES MARKET
6.8 TRADE ANALYSIS
6.8.1 IMPORT DATA (HS CODE 300220)
6.8.2 EXPORT DATA (HS CODE 300220)
6.9 PORTER'S FIVE FORCES ANALYSIS
6.9.1 THREAT OF NEW ENTRANTS
6.9.2 THREAT OF SUBSTITUTES
6.9.3 BARGAINING POWER OF SUPPLIERS
6.9.4 BARGAINING POWER OF BUYERS
6.9.5 INTENSITY OF COMPETITIVE RIVALRY
6.10 PATENT ANALYSIS
6.10.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2014-2024
6.11 KEY CONFERENCES & EVENTS, 2025-2026
6.12 KEY STAKEHOLDERS & BUYING CRITERIA
6.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.12.2 KEY BUYING CRITERIA
6.13 INVESTMENT & FUNDING SCENARIO
6.14 IMPACT OF AI/GENERATIVE AI ON VACCINES MARKET
6.14.1 INTRODUCTION
6.14.2 MARKET POTENTIAL OF AI IN VACCINES MARKET
6.14.3 AI USE CASES
6.14.4 KEY COMPANIES IMPLEMENTING AI
6.14.5 FUTURE OF GENERATIVE AI IN VACCINES ECOSYSTEM
6.15 IMPACT OF 2025 US TARIFFS ON VACCINES MARKET
6.15.1 INTRODUCTION
6.15.2 KEY TARIFF RATES
6.15.3 PRICE IMPACT ANALYSIS
6.15.4 IMPACT ON COUNTRY/REGION
6.15.4.1 US
6.15.4.2 Europe
6.15.4.3 Asia Pacific
6.15.5 IMPACT ON END-USE INDUSTRIES
6.15.5.1 Public health & government bodies
6.15.5.2 Healthcare providers & institutions
6.16 VACCINE PROCUREMENT DATA
6.16.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2023-2025
6.16.2 WHO: VACCINE PURCHASE DATABASE, 2021-2023
6.17 VACCINE MANUFACTURING PROCESS
6.17.1 OVERVIEW
6.17.1.1 R&D and process development
6.17.1.2 Upstream production (antigen generation)
6.17.1.3 Downstream processing
6.17.1.4 Formulation & fill-finish
6.17.1.5 Quality control & regulatory release
6.17.1.6 Packaging, cold chain, and distribution
6.17.2 MANUFACTURING MODELS & CAPACITY DYNAMICS

7 VACCINES MARKET, BY DISEASE INDICATION
7.1 INTRODUCTION
7.2 PNEUMOCOCCAL DISEASE
7.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
7.3 INFLUENZA
7.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
7.4 COMBINATION VACCINES
7.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINES TO DRIVE MARKET GROWTH
7.5 HPV
7.5.1 RISING FOCUS ON CERVICAL CANCER PREVENTION TO DRIVE HPV VACCINE UPTAKE
7.6 MENINGOCOCCAL DISEASE
7.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO SUPPORT MARKET GROWTH
7.7 HERPES ZOSTER
7.7.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
7.8 ROTAVIRUS
7.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS VACCINE MARKET GROWTH
7.9 MMR
7.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND
7.10 VARICELLA
7.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
7.11 HEPATITIS
7.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
7.12 DTP
7.12.1 STRONG INTEGRATION INTO NATIONAL IMMUNIZATION PROGRAMS TO SUSTAIN DTP VACCINE DEMAND
7.13 POLIO
7.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
7.14 RSV
7.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH
7.15 COVID-19
7.15.1 DECLINING DEMAND DUE TO HIGH POPULATION COVERAGE AND REDUCED SEVERITY OF VARIANTS TO SLOW DOWN MARKET GROWTH
7.16 OTHER DISEASE INDICATIONS

8 VACCINES MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
8.2.1 CONJUGATE VACCINES
8.2.1.1 Increasing public-private partnerships to drive market growth
8.2.2 RECOMBINANT VACCINES
8.2.2.1 Low post-vaccination reactions and reduced need for booster doses to drive market
8.2.3 INACTIVATED & SUBUNIT VACCINES
8.2.3.1 Ease of storage and transportation to support growth
8.2.4 LIVE ATTENUATED VACCINES
8.2.4.1 High cost of storage and limited financial resources of distributors to restrain market
8.2.5 TOXOID VACCINES
8.2.5.1 Rising prevalence of bacterial infections among infants and children to drive market
8.2.6 OTHER VACCINES
8.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
8.3.1 MRNA VACCINES
8.3.1.1 Increasing focus on mRNA vaccine development to drive market
8.3.2 VIRAL VECTOR VACCINES
8.3.2.1 Rising investment in vaccine development to drive market
8.3.3 OTHER COVID-19 VACCINES

9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE
9.1 INTRODUCTION
9.2 MULTIVALENT VACCINES
9.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
9.3 MONOVALENT VACCINES
9.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH

10 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION
10.1 INTRODUCTION
10.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
10.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
10.3 ORAL ADMINISTRATION
10.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION
10.4 OTHER ROUTES OF ADMINISTRATION

11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER
11.1 INTRODUCTION
11.2 ADULT VACCINES
11.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD
11.3 PEDIATRIC VACCINES
11.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET

12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 US to dominate North American market during forecast period
12.2.3 CANADA
12.2.3.1 High incidence of infectious diseases to drive market growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Significant R&D investments and growing biotechnology industry to drive market
12.3.3 UK
12.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market
12.3.4 FRANCE
12.3.4.1 Favorable government initiatives for mass immunization to drive market
12.3.5 ITALY
12.3.5.1 Higher investments by companies for increased production capacities to drive market
12.3.6 SPAIN
12.3.6.1 Rising investments in vaccine development by private organizations to drive market
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 China to hold largest share of APAC vaccines market
12.4.3 JAPAN
12.4.3.1 Favorable government initiatives to support market growth
12.4.4 INDIA
12.4.4.1 Increasing government initiatives and development of new and improved vaccines to drive market
12.4.5 SOUTH KOREA
12.4.5.1 Strong government strategies for improved vaccine hubs to drive market
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Rising focus on immunization programs to drive market
12.5.3 MEXICO
12.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.7 AFRICA
12.7.1 AVAILABILITY OF FUNDS AND GRANTS FROM DEVELOPED ECONOMIES TO DRIVE MARKET
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
13.3 REVENUE ANALYSIS, 2020-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Technology footprint
13.5.5.4 Type footprint
13.5.5.5 Route of administration footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
13.6.5.1 Detailed list of key startups/SMEs
13.6.5.2 Competitive benchmarking of key startups/SMEs
13.7 COMPANY VALUATION & FINANCIAL METRICS
13.7.1 FINANCIAL METRICS
13.7.2 COMPANY VALUATION
13.8 BRAND/PRODUCT COMPARISON
13.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES & APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 GSK PLC
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches & approvals
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 MERCK & CO., INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 PFIZER INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product approvals
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 SANOFI
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product approvals
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.4.3.4 Other developments
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses & competitive threats
14.1.5 CSL
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product approvals
14.1.5.3.2 Deals
14.1.5.3.3 Expansions
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses & competitive threats
14.1.6 EMERGENT
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product approvals
14.1.6.3.2 Other developments
14.1.7 JOHNSON & JOHNSON SERVICES, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 ASTRAZENECA
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.8.3.2 Expansions
14.1.8.3.3 Other developments
14.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches & approvals
14.1.9.3.2 Deals
14.1.9.3.3 Expansions
14.1.10 BAVARIAN NORDIC
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product approvals
14.1.10.3.2 Deals
14.1.10.3.3 Other developments
14.1.11 MITSUBISHI TANABE PHARMA CORPORATION
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches & approvals
14.1.11.3.2 Deals
14.1.12 DAIICHI SANKYO COMPANY, LIMITED
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 PANACEA BIOTEC
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Deals
14.1.14 BIOLOGICAL E LIMITED
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Product approvals
14.1.14.3.2 Deals
14.1.14.3.3 Other developments
14.1.15 BHARAT BIOTECH
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches & approvals
14.1.15.3.2 Deals
14.1.16 NOVAVAX
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Product approvals
14.1.17 INOVIO PHARMACEUTICALS
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Other developments
14.2 OTHER PLAYERS
14.2.1 SINOVAC
14.2.2 INCEPTA PHARMACEUTICALS LTD.
14.2.3 VALNEVA SE
14.2.4 VBI VACCINE INC.
14.2.5 BIO FARMA
14.2.6 MICROGEN
14.2.7 ZHI FEI BIOLOGICAL
14.2.8 INDIAN IMMUNOLOGICALS LIMITED

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS